Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
08/2010
08/17/2010US7776820 Methods for decreasing risk of complications of prematurity using IGF-I and its analogs
08/17/2010US7776552 Drug screening; for inhibiting apoptosis in mammalian cells; zinc finger domains; consensus sequences; genetic engineering; for treating AIDS, alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, autoimmune diseases
08/17/2010US7776369 lignan extract comprising a lignan complex including secoisolariciresinol diglucoside;wherein the lignan extract is substantially free of cyanogenic glycosides as determined by measuring free cyanides; use in treating cancer, diabetes, hypertension, lupus, and atherosclerosis
08/17/2010US7776345 Gastric retention controlled drug delivery system
08/17/2010US7776319 Methods and compositions for treatment of ion imbalances
08/17/2010US7775469 treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent
08/17/2010CA2557538C Benzimidazole derivative and use as an angiotensin ii receptor antagonist
08/17/2010CA2481535C Use of ep4 receptor ligands in the treatment of il-6 involved diseases
08/17/2010CA2473203C Orodispersible pharmaceutical composition comprising ivabradine
08/17/2010CA2471762C Cell-permeable peptide inhibitors of the jnk signal transduction pathway
08/17/2010CA2461963C Cyclic amine compounds
08/17/2010CA2455296C 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors
08/17/2010CA2431974C Urea and urethane derivatives as integrin inhibitors
08/17/2010CA2412854C Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
08/17/2010CA2411436C A method for detecting protein inhibitors and ligands
08/17/2010CA2403086C Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
08/17/2010CA2385269C Novel thiazolo(4,5-d)pyrimidine compounds
08/17/2010CA2383814C Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same
08/17/2010CA2382940C 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
08/17/2010CA2378165C Dihydrobenzodiazepines and their use in the treatment of dyslipidaemia
08/17/2010CA2337828C Phosphinic and phosphonic acid derivatives used as pharmaceuticals
08/17/2010CA2325471C Piperididinyl and n-amidinopiperidinyl derivatives
08/17/2010CA2290742C Use of galt-2 inhibitor compounds to treat conditions associated with lactosylceramide
08/12/2010WO2010090222A1 Hb-egf-bound protein complex
08/12/2010WO2010090200A1 Phenylimidazole compounds
08/12/2010WO2010089712A2 Formulation for the treatment of hypoxia and related disorders
08/12/2010WO2010089510A2 Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
08/12/2010WO2010089475A1 Novel method for the synthesis of ivabradine and the pharmaceutically acceptable acid addition salts thereof
08/12/2010WO2010089379A1 Method and means for producing tissues and tissues obtained
08/12/2010WO2010069090A3 Pharmaceutical composition containing angiotensin-(1-9) for cardiovascular, pulmonary and/or cerebral treatment
08/12/2010WO2010054126A3 Small molecule modulators of epigenetic regulation and their therapeutic applications
08/12/2010WO2010054015A3 Methods of reducing the risk of cardiovascular disease in postmenopausal women
08/12/2010WO2010039977A3 Heteroaryl antagonists of prostaglandin d2 receptors
08/12/2010WO2010011546A3 Pyrrolo [3, 2-b]pyridines and pyrazolo [4, 3 -b] pyridines having 5-ht6 receptor affinity
08/12/2010WO2009109616A8 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
08/12/2010US20100204336 Formoterol Tartrate Process and Polymorph
08/12/2010US20100204332 Method for treating a disease or condition responsive to opening of c1c-2 channel
08/12/2010US20100204288 Heteroaryl-Ureas and Their Use as Glucokinase Activators
08/12/2010US20100204278 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
08/12/2010US20100204276 Indole compounds, a process for their preparation and pharmaceutical compositions containing them
08/12/2010US20100204268 Processes for preparing different forms of (s)-(+)-clopidogrel bisulfate
08/12/2010US20100204252 Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
08/12/2010US20100204249 Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
08/12/2010US20100204241 New pyridazin-3(2h)-one derivatives
08/12/2010US20100204238 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
08/12/2010US20100204236 Substituted imidazoles as bombesin receptor subtype-3 modulators
08/12/2010US20100204227 Isoindoline compounds and methods of their use
08/12/2010US20100204226 Quinazolinones as prolyl hydroxylase inhibitors
08/12/2010US20100204222 Pyridopyrimidine derivatives as p13 kinase inhibitors
08/12/2010US20100204218 Fused bicyclic compound
08/12/2010US20100204213 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
08/12/2010US20100204212 Fused heterocyclic compounds useful as kinase modulators
08/12/2010US20100204207 Compounds and Methods for Treating Dyslipidemia
08/12/2010US20100204206 Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them
08/12/2010US20100204199 Cyclic 11-beta hydroxysteroid dehydrogenase type i inhibitors
08/12/2010US20100204197 Pyrrolopyrimidines
08/12/2010US20100204195 Pharmaceutical Compositions and Process for Making Them
08/12/2010US20100204194 Superoxide dismutase mimics for the treatment of ocular disorders and diseases
08/12/2010US20100204190 New combinations
08/12/2010US20100204188 Method of synergistically enhancing the therapeutic efficacy and safety of medications through a combination therapy
08/12/2010US20100204179 Resveratrol complex and process for the preperation
08/12/2010US20100204163 Metabolites and derivatives of ambrisentan
08/12/2010US20100204160 Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof
08/12/2010US20100204157 Use of a peptide as a therapeutic agent
08/12/2010US20100204156 Use of thymopentin as a therapeutic agent
08/12/2010US20100204155 Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents
08/12/2010US20100204154 Use of the peptide rfmwmr as a therapeutic agent
08/12/2010US20100204153 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection
08/12/2010US20100204152 Use of gluten exorphin c : as a therapeutic agent
08/12/2010US20100204151 Use of a peptide as a therapeutic agent
08/12/2010US20100204150 Use of a peptide as a therapeutic agent
08/12/2010US20100204149 Use of octreotide as a therapeutic agent
08/12/2010US20100204148 (d-leu7 ) -histrelin as a therapeutic agent
08/12/2010US20100204145 Use of a peptide as a therapeutic agent
08/12/2010US20100204144 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents
08/12/2010US20100204143 Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
08/12/2010US20100204142 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
08/12/2010US20100204141 Use of bpp-b as a therapeutic agent
08/12/2010US20100204140 Use of a peptide as a therapeutic agent
08/12/2010US20100204139 Use of gonadorelin as a therapeutic agent
08/12/2010US20100204138 Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents
08/12/2010US20100204136 Use of a peptide as a therapeutic agent
08/12/2010US20100204135 Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s)
08/12/2010US20100204134 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent
08/12/2010US20100204132 THERAPEUTIC USES OF PEPTIDES YSAYPDSVPMMS and WMNSTGFTKVCGAPPC
08/12/2010US20100204131 Use of a peptide as a therapeutic agent
08/12/2010US20100204130 Use of human neuropeptide as a therapeutic agent
08/12/2010US20100204129 Use of a peptide as a therapeutic agent
08/12/2010US20100204124 Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members
08/12/2010US20100204123 Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease
08/12/2010US20100204118 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents
08/12/2010US20100204117 Cgrp as a therapeutic agent
08/12/2010US20100204116 Use of calcitonin as anti-angiogenic agent
08/12/2010US20100204114 Use of a galanin peptide as a therapeutic agent
08/12/2010US20100204113 Use of stresscopin-related peptide as a therapeutic agent
08/12/2010US20100204112 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
08/12/2010US20100204111 Astressin and beta- endorphin for use as therapeutic agents
08/12/2010US20100204110 Use of a peptide as a therapeutic agent
08/12/2010US20100204109 Use of c-type natriuretic peptide, alone or in combination with neuropeptide af, as a therapeutic agent
08/12/2010US20100204108 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents
1 ... 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 ... 1595